Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: A double-blind, randomized study in acutely agitated patients with dementia

Neuropsychopharmacology

Volumn 26, Issue 4, 2002, Pages 494-504

  Meehan, Karena M ^a   Wang, Huei ^a   David, Stacy R ^a   Nisivoccia, Jennifer R ^a   Jones, Barry ^a   Beasley Jr , Charles M ^a   Feldman, Peter D ^a   Mintzer, Jacobo E ^b   Beckett, Louise M ^c   Breier, Alan ^a  

^a ELI LILLY AND COMPANY   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Agitation; Dementia; Intramuscular injections; Lorazepam; Olanzapine; PANSS

Indexed keywords

LORAZEPAM; OLANZAPINE; PLACEBO;

ADULT; AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEDATION; SINUS BRADYCARDIA; SOMNOLENCE; STANDING; TACHYCARDIA; VASODILATATION;

ACUTE DISEASE; AGED; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DEMENTIA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; LORAZEPAM; MALE; MIDDLE AGED; PIRENZEPINE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION;

EID: 0036195522     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(01)00365-7     Document Type: Article

References (52)

1. Pilot study of haloperidol, fluoxetine, and placebo in Alzheimer's disease
2. Psychotropic drugs in the elderly: Selection of the appropriate agent
3. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study
4. Influence of route of administration on haloperidol plasma levels in psychotic patients
5. Incidence and predictors of drug-induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics
6. The impact of private residential and nursing care on statutory residential and hospital care of elderly people in south Belfast
7. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease
8. Optimal management of behavioural disorders associated with dementia
9. Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated
10. Medical correlates of agitation in nursing home residents
11. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia
12. Agitation and other noncognitive abnormalities in Alzheimer's disease
13. Neuroleptic treatment of agitation and psychosis in dementia
14. Rapid tranquilization: The efficacy of oral concentrate
15. Treatment of agitation in older persons with dementia
16. Mini-Mental State. A practical method for grading the cognitive state of patients by the clinician
17. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting
18. The application of the principle of intention-to-treat to the analysis of clinical trials
19. Extrapyramidal signs, primitive reflexes and frontal lobe function in senile dementia of the Alzheimer type
20. Diazepam versus lorazepam: Relationship of drug distribution to duration of clinical action
21. Epidemiology of psychopathology in old age: Some implications for clinical services
22. Tolerability and pharmacokinetics of remoxipride after intramuscular administration
23. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial
24. Pyramidical model of schizophrenia
25. Pharmacologic approach to management of agitation associated with dementia
26. Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS)
27. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: A review of the literature
28. Five factor model of schizophrenia: Replication across samples
29. Nursing home care as an alternative to psychiatric hospitalization: A Veterans Administration cooperative study
30. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs
31. Side effects of antipsychotics in the elderly
32. Variability of the QTc interval: Impact on defining drug effect and low-frequency cardiac event
33. Abnormal behavior of elderly people residing in institutions of medical and social welfare systems
34. The Brief Psychiatric Rating Scale
35. Fluphenazine decanoate causing atrioventricular block
36. Use of benzodiazepines to control disruptive behavior in inpatients
37. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior
38. Olanzapine versus haloperidol treatment in first-episode psychosis
39. Bioavailability of intramuscular versus oral haloperidol in schizophrenic patients
40. A metaanalysis of controlled trials of neuroleptic treatment in dementia
41. A clinical guide to antipsychotic drugs
42. Clinical and plasma level characteristics of intramuscular and oral loxapine
43. The dementia syndrome
44. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial
45. Cognitive and behavioural impairment among elderly people in institutions providing different levels of care
46. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
47. Component structure of the Positive and Negative Syndrome Scale (PANSS) in patients with recent onset schizophrenia and spectrum disorders
48. The use of the Neuropsychiatric Inventory in nursing home residents. Characterization and measurement
49. A double-blind study of intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients